S&P Futures
3,925.50 +21.75 (+0.56%) Dow Futures
31,607.00 +186.00 (+0.59%) Nasdaq Futures
12,101.50 +61.00 (+0.51%) Russell 2000 Futures
1,782.90 +13.10 (+0.74%) Crude Oil
111.43 +1.86 (+1.70%) Gold
1,824.90 +0.10 (+0.01%)
Xencor, Inc. (XNCR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 27.12 |
| Open | 26.63 |
| Bid | 11.08 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 26.55 - 27.82 |
| 52 Week Range | 19.35 - 43.61 |
| Volume | |
| Avg. Volume | 382,348 |
| Market Cap | 1.653B |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | 15.60 |
| EPS (TTM) | 1.78 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for XNCR
Related Research
- Xencor, Inc.XNCR: Raising target price to $26.00XENCOR INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat6 days agoArgus Research
- Business Wire
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
MONROVIA, Calif., May 26, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumors (DUET-3). These results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), during the poster
- InvestorPlace
7 High-Risk, High-Reward Small-Cap Stocks to Buy Now
On a valuation basis, these small-cap stocks could be stocks to buy for long-term gains. Monro (MNRO): A good-quality stock you can buy now or wait for lower prices in. Jack in the Box (JACK): A well-known franchise with a low-priced valuation. Ultra Clean Holdings (UCTT): Its low valuation and growing earnings make it a stock to buy. Patrick Industries (PATK): It remains a stock to buy, even in this market environment. Xencor (XNCR): It had weak earnings, but watch this stock for a buying point
- Simply Wall St.
Declining Stock and Decent Financials: Is The Market Wrong About Xencor, Inc. (NASDAQ:XNCR)?
Xencor (NASDAQ:XNCR) has had a rough three months with its share price down 20%. But if you pay close attention, you...
